胰腺癌肿瘤标志物对胰腺癌早期诊断的研究进展

Research Progress of Tumor Markers for Early Diagnosis of Pancreatic Cancer

胰腺癌是一种临床表现隐匿、发展迅速和预后极差的消化系统肿瘤,在西方国家是癌症死亡的主要原因之一,也是我国消化系统肿瘤的主要死亡原因之一,其早期诊断和手术治疗可显著提高患者生存率、明显改善预后。近年对胰腺癌的肿瘤标志物进行了大量研究,CA19-9、CA50、CA242等均是目前临床诊断胰腺癌的常用标志物,但迄今为止仍未找到一种对早期胰腺癌有足够敏感性、特异性的肿瘤标志物来进行肿瘤筛查。单独血清指标的特异性和敏感性尚不能满足临床诊断早期胰腺癌的需要,因此需要寻找新的肿瘤标志物,并有效组合联合诊断的方法来进一步提高胰腺癌的诊疗水平。

Pancreatic cancer is a kind of digestive system tumor with occult clinical manifestations, rapid development and poor prognosis, which is not only one of the leading causes of death from cancer in West, but also one of the main causes of death from digestive system tumors in China, and its early diagnosis and surgical treatment can significantly improve patients’ survival rate and prognosis. In recent years, a lot of studies have been carried out on tumor markers of pancreatic cancer, and such as CA19-9, CA50, CA242 are commonly used in clinical diagnosis, yet there isn’t a kind of tumor marker that is sensitive and specific enough to pancreatic cancer for tumor screening. The specificity and sensitivity of every single serum index cannot meet the needs of early diagnosis for pancreatic cancer yet, therefore it’s necessary to find some new tumor markers and effectively combine the diagnostic methods to further improve the diagnosis and treatment level of pancreatic cancer.